FindTrial
Sign In

rhIL-15

DRUG5 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Anaplastic Large Cell LymphomaB-CellChronicClear-Cell Renal CarcinomaLeukemiaLymphocyticMetastatic Solid TumorsMycosis Fungoides

Phase 1

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
CompletedNCT03388632
National Cancer Institute (NCI)Metastatic Solid Tumors, Treatment-Refractory Cancers
Start: 2018-02-05End: 2025-05-08Updated: 2025-12-18
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
TerminatedNCT03759184
National Cancer Institute (NCI)B-Cell, Chronic, Leukemia +1
Start: 2019-07-11End: 2021-10-22Updated: 2022-03-22
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
CompletedNCT03905135
National Cancer Institute (NCI)Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Peripheral T-cell Lymphoma NOS +1
Start: 2019-06-07End: 2022-05-17Updated: 2022-09-13
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RecruitingNCT06995872
National Cancer Institute (NCI)Neuroblastoma
Start: 2025-10-21End: 2029-06-01Target: 34Updated: 2026-02-17

Phase 2

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
TerminatedNCT04150562
National Cancer Institute (NCI)Clear-Cell Renal Carcinoma
Start: 2020-05-26End: 2021-09-16Updated: 2022-05-17

Related Papers

Phase 1 study of recombinant interleukin 15 in combination with nivolumab and ipilimumab in subjects with refractory cancers.
Journal of Clinical Oncology2025-05-28
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Journal for ImmunoTherapy of Cancer2023-10-0122 citations
Abstract CT147: Phase 1 study of recombinant interleukin 15 (rhIL-15) in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers
Cancer Research2022-06-151 citations
Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
Blood Advances2022-04-2719 citations
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Journal for ImmunoTherapy of Cancer2021-11-0143 citations
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies
Journal for ImmunoTherapy of Cancer2021-04-0143 citations
IL-15 in the Combination Immunotherapy of Cancer.
2020-05-19183 citations
Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers
Clinical Research (Excluding Clinical Trials)2019-07-01
Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers
Cancer Research2019-07-01
Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers.
Journal of Clinical Oncology2018-05-202 citations